Application of ARR layered diagnose new tangency point to preparation of reagent kit for screening of primary aldosteronism

Abstract

The invention discloses an application of an aldosterone/renin ratio layered diagnose new tangency point to preparation of a reagent kit for screening of primary aldosteronism. The application is characterized in that primary aldosteronism high-risk crowds are layered according to eGFR, (1) for a part of crowds of which the eGFR is greater than or equal to 90ml/min/1.73m<2>, an ARR tangency pointis 52ng/dl per ng/ml.h; and (2) for a part of crowds of which the eGFR is smaller than 90ml/min/1.73m<2>, the ARR tangency point is 18ng/dl per ng/ml.h. According to the application disclosed by the invention, a glomerular filtration rate prior estimate (eGFR) is used as a leading indicator for reflecting renal functions, and the relevance of eGFR and ARR is researched, so that the optimal screening tangency point suitable for different kinds of high-risk crowds is formulated, sensibility and specificity of primary aldosteronism screening test are improved, and the diagnosis and treatment level of the primary aldosteronism is increased. The aldosterone/renin ratio layered diagnose new tangency point is easy in standardization and hopeful in further promotion, and has favorable applicationvalue for early screening and diagnosis of the primary aldosteronism.

Description

technical field [0001] The invention belongs to the field of disease screening and treatment, and in particular relates to the application of a new cut-off point for stratified diagnosis of aldosterone / renin ratio in the screening of primary aldosteronism. Background technique [0002] Studies have reported that primary aldophylaxis accounts for 5% to 10% of hypertensive populations, and is as high as 20% in patients with resistant hypertension. It is a common endocrine hypertension. Due to the high prevalence, low detection rate, and high cardiovascular risk of PADS, the new guidelines clearly state that the diagnosis and treatment of PADS should be regarded as a public health problem, not just the diagnosis and treatment of a certain patient question. Similar to the situation in foreign countries, at present, the detection rate of PAS in China is low and the misdiagnosis rate is high. The reasons include: insufficient understanding and attention to PAS; the diagnostic pro...

AI Technical Summary

Problems solved by technology

On the one hand, if the screening criteria for patients with normal renal function are adopted for high-risk groups, the change of eGFR-related ARR values ​​may lead to an increased risk of misdiagnosis in hypertensive patients; Increased false positive rate

[0005] Because ARR is affected by many fact